Size isn't everything
- 20 September 2002
- journal article
- review article
- Published by Wiley in Statistics in Medicine
- Vol. 21 (19) , 2807-2814
- https://doi.org/10.1002/sim.1284
Abstract
Clinical trials now often involve thousands of patients, and statisticians emphasize the importance of trial size in ensuring that ‘correct’ answers are obtained. However, when a good treatment appears for a disease that was hitherto untreatable – for example, oranges for scurvy or streptomycin for tuberculosis – only a small trial is needed. Large trials are only needed to demonstrate small effects. The meta‐analysis of small trials is often misleading, and may hide undesirable effects of individual drugs. The concept of equivalence between treatments is important, and while a statistically adequate equivalence trial may have to be very large, many clinicians will question the need for extreme statistical propriety. Clinical trials often do not reflect ‘real world’ practice, and the clinical relevance of a trial is more important than its size. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 20 references indexed in Scilit:
- Discrepancies between Meta-Analyses and Subsequent Large Randomized, Controlled TrialsNew England Journal of Medicine, 1997
- The Effect of Digoxin on Mortality and Morbidity in Patients with Heart FailureNew England Journal of Medicine, 1997
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarctionPublished by Elsevier ,1992
- In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparinThe Lancet, 1990
- TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1988
- Beta blockade during and after myocardial infarction: An overview of the randomized trialsProgress in Cardiovascular Diseases, 1985
- Surgery of Congenital Heart DiseaseBMJ, 1948
- FURTHER OBSERVATIONS ON PENICILLINThe Lancet, 1941